LIDDS (LIDDS) Q3 2025 earnings summary

Executive summary

• No net sales were recorded for Q3 or the nine-month period; the company remains pre-revenue.

• Operating and net losses narrowed year-over-year, with Q3 net loss at -891 KSEK and nine-month net loss at -2,935 KSEK.

• Major strategic shift: development of Nanodotax, Nanoimod, and NOV202 projects ceased in April 2025.

• Board determined equity was less than half of share capital, triggering a balance sheet for liquidation and a control meeting; decision made to continue operations.

Financial highlights

• Q3 2025: Net sales 0 KSEK (unchanged), operating result -876 KSEK (improved from -1,061 KSEK), net result -891 KSEK (vs. -877 KSEK), EPS -0.01 SEK (unchanged).

• Jan–Sep 2025: Net sales 0 KSEK, operating result -2,967 KSEK (improved from -3,453 KSEK), net result -2,935 KSEK (vs. -3,296 KSEK), EPS -0.02 SEK (vs. -0.03 SEK).

• Cash flow from operating activities for Jan–Sep 2025 was -2,949 KSEK (improved from -4,451 KSEK).

• Cash and cash equivalents at period end: 1,733 KSEK (down from 6,552 KSEK year prior).

• Equity ratio at 75% as of September 30, 2025; equity at 1,492 KSEK.

Outlook and guidance

• Cash is expected to last through Q1 2026 if current cost levels are maintained; additional financing will be needed if costs rise.

• Extraordinary general meeting in December to decide on reducing share capital to 500 KSEK to restore equity.